Related Experiment Video
Updated: Jul 4, 2026
10:04
Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
Published on: May 1, 2015
[Therapy of multiple myeloma]
G La Verde1, A Pulsoni, M T Petrucci
1Dipartimento di Biopatologia Umana, Università La Sapienza, Roma.
Recenti Progressi in Medicina
|April 1, 1997
Summary
Melphalan-prednisone remains a top treatment for older multiple myeloma patients. Younger patients benefit from high-dose therapy, and interferon can extend response duration.
Area of Science:
- Hematology
- Oncology
- Clinical Medicine
Background:
- The melphalan-prednisone combination revolutionized multiple myeloma treatment in the 1960s.
- Despite advancements, melphalan-prednisone is still a preferred regimen for elderly multiple myeloma patients.
- Current research focuses on optimizing treatment strategies for different patient age groups.
Purpose of the Study:
- To review current therapeutic approaches for multiple myeloma.
- To discuss the efficacy of various treatment modalities in different patient populations.
- To highlight advancements in managing multiple myeloma and its complications.
Main Methods:
- Review of historical and contemporary clinical data on multiple myeloma treatment.
- Analysis of outcomes associated with melphalan-prednisone therapy.
- Evaluation of high-dose therapy and interferon maintenance strategies.
Main Results:
- Melphalan-prednisone demonstrates sustained efficacy in patients over 60-65 years.
- High-dose therapy has significantly improved tumor reduction and survival in younger patients.
- Interferon maintenance therapy prolongs response phases after initial treatment.
Conclusions:
- Melphalan-prednisone remains a cornerstone for elderly multiple myeloma patients.
- High-dose therapy offers significant benefits for younger individuals.
- Further research into managing multiple myeloma and its complications is ongoing.
More Related Videos
09:41An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
05:32Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
Published on: January 7, 2019
Related Concept Videos
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.